Hazel Wilkie

Jul 12, 2024 | sciencedirect.com | Hazel Wilkie |Raif S. Geha

Disclosure of potential conflict of interest: J. E. Gudjonsson has served as an advisor to Janssen, Almirall, Eli Lilly, Novartis, Sanofi, AbbVie, Merck, BMS, and Boehringer Ingelheim and has received research grants from Janssen, Boehringer Ingelheim, Almirall, Eli Lilly, Novartis, Merck and BMS. S. Weidinger has received institutional research grants from LEO Pharma, Pfizer, and Sanofi; has been an advisor and/or received speakers honoraria from AbbVie, Almirall, Boehringer, Eli Lilly,

Apr 23, 2024 | sciencedirect.com | Hazel Wilkie |Raif S. Geha |Eun-Kyung Kwon |Ga-Young Ban

Section snippetsStudy designThis phase 2, randomized, double-blind, placebo-controlled trial (NCT04444752) was conducted across 59 sites in the United States (38), China (9), Australia (8), and New Zealand (4). The trial comprised a 45-day screening period, a 16-week treatment period, and an 8-week follow-up period (see Fig E1 in this article’s Online Repository at www.jacionline.org).

Dec 2, 2023 | sciencedirect.com | Ottavia Delmonte |Luigi D. Notarangelo |Hazel Wilkie |Raif S. Geha

Section snippetsMethodsDetailed methods are presented in the Methods section in this article’s Online Repository (available at www.jacionline.org). Briefly, the imputed Immunochip data of patients with CVID (n = 299) and controls (n = 900) were selected from the database of Center for Applied Genomics, the Children’s Hospital of Philadelphia (CHOP) and were used to compute the linkage disequilibrium between SNPs at the CLEC16A intron 19 region for fine-mapping.